A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Intrathecal Administration of RO7234292 (RG6042) in Patients with Manifest Huntington's Disease
Phase 5 study testing RG6042 in Huntington's disease.
Active, not recruiting5DrugJPRNTreatment trial
Recruiting in: Japan
Preparing a short plain-English summary.